Angiohematopoietic Progenitor Cell Purification via Marker Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating hematopoietic stem cells from human pluripotent stem cells face challenges in identifying and isolating well-defined populations of hemogenic endothelial cells, which are crucial for de novo blood cell formation and therapeutic applications, due to limitations in marker specificity and utility in vitro.
Innovation Solution
A purified human cell population characterized by specific markers such as VE-cadherin−, KDRbright, APLNR+, PDGFRαlow, and CD117 intermediate expression, enabling the identification and isolation of hemogenic endothelial progenitors and angiogenic hematopoietic progenitors, which can form hematoendothelial colonies with high frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If VE-cadherin+CD41a− and/or CD45− phenotype is used for detection and isolation of hemogenic endothelial cells, then the entire population of endothelial cells is covered, but the method does not fully exclude hematopoietic cells and does not discriminate between endothelial lineages with restricted primitive hematopoietic and multipotential definitive potentials
Solution Approach 1:
The invention segments the endothelial cell population into distinct subsets based on marker expression patterns. By combining VE-cadherin with other markers (CD41a, CD45, CD34, CD144, CD31) in specific combinations, the method divides the broad endothelial population into functionally distinct groups including hemogenic endothelial cells, definitive hematopoietic progenitors, and other endothelial subsets, enabling precise discrimination while maintaining comprehensive coverage
Solution Approach 2:
The invention applies local quality by assigning different marker expression requirements to different endothelial subpopulations. Each subset is defined by specific marker combinations that highlight their unique functional characteristics - for example, VE-cadherin+CD41a−CD45− for hemogenic endothelial cells versus VE-cadherin+CD34+CD144+ for definitive hematopoietic progenitors, allowing tailored identification based on local functional needs
2Measurement precision
If anatomical location, morphology, and Runx1 expression are used to identify definitive hemogenic endothelial cells in embryos, then precise identification is achieved, but these criteria cannot be entirely applied to cells differentiated in vitro
Solution Approach 1:
The invention creates a copy of the in vivo identification system by establishing marker expression profiles that mirror the anatomical and molecular characteristics of definitive hemogenic endothelial cells in the AGM region. The VE-cadherin+CD41a−CD45− and VE-cadherin+CD34+CD144+ marker combinations replicate the functional identity of embryonic hemogenic endothelium, allowing in vitro differentiated cells to be identified with the same precision as in vivo cells without requiring anatomical context
Solution Approach 2:
The invention transitions from anatomical and morphological parameters (which cannot be applied in vitro) to molecular marker expression parameters that can be measured in cell culture. By changing the identification parameters from physical location and morphology to surface marker expression patterns, the method maintains high identification accuracy while becoming fully applicable to in vitro differentiated cell populations
3Productivity
If direct mesodermal precursor of hemogenic endothelial cells is targeted, then de novo generation of HSCs from hPSCs can be achieved, but the precise identification and isolation of these precursors remains a significant challenge
Solution Approach 1:
The invention performs preliminary action by identifying and isolating mesodermal precursors before they fully differentiate into hemogenic endothelial cells. The method uses intermediate marker expressions (such as VE-cadherin−KDRbrightAPLNR+PDGFRαlow and VE-cadherin+CD73−CD235a/CD43−) to capture cells at transitional stages, enabling their isolation and further differentiation into HSCs with higher efficiency than waiting for definitive HE marker expression
Data Source
AI summary
A purified human cell population of subsets of angiohematopoietic progenitor cells, wherein the population is at least 94% pure and wherein the cells are selected with cell markers selected from the group of KDR, APLNR, VE-cadherin, PDGFRα, CD31, CD235a, CD73, CD43, and CD41a.